DNA RNA and Cells

20 June 2013

Alnylam Scientists Present Pre-clinical Data with ALN-CC5, an RNAi Therapeutic Targeting Complement Component C5 for the Treatment of Complement-Mediated Diseases

19 June 2013

Sarepta Therapeutics Announces Eteplirsen Demonstrates a Continued Benefit on Walking Test Through 84 Weeks in Phase IIb Study in Duchenne Muscular Dystrophy

18 June 2013

iCo Therapeutics Announces Completion of Trial Enrollment and Clinical Update for iDEAL Phase 2 Study for the Treatment of Diabetic Macular Edema

18 June 2013

OncoSec Medical Announces Completion of Enrollment of Phase II Metastatic Melanoma Trial

17 June 2013

Updated Results from Geron’s Imetelstat Phase 2 Proof-of-Concept Trial in Essential Thrombocythemia Presented at the European Hematology Association Congress

13 June 2013

As the First Biopharmaceutical Company Worldwide, apceth Receives Approval for a Clinical Trial with Genetically Modified Adult Mesenchymal Stem Cells for the Treatment of Cancer

12 June 2013

Qu Biologics Enrolls First Patient in Phase 1/2 Clinical Trial of QBECO SSI for the Treatment of Crohn’s Disease

11 June 2013

SanBio Announces FDA Clearance for the Initiation of a Phase I/2a Clinical Trial Testing Their Cell Therapy Product, SB623, in Patients with Traumatic Brain Injury

6 June 2013

RXi Pharmaceuticals Announces Positive Results in its First Double Blind Study in Healthy Volunteers with RXI-109

5 June 2013

EGEN, Inc. Advances a Systemically Delivered RNAi Therapeutic for the Treatment of Pulmonary Arterial Hypertension (PAH)

5 June 2013

Idera Pharmaceuticals Announces Initiation of a Phase 2 Trial of IMO-8400 in Patients with Moderate to Severe Plaque Psoriasis

4 June 2013

Pluristem to Receive Clinical-hold Notice From the U.S. FDA

4 June 2013

Isis Pharmaceuticals Reports Encouraging Data on ISIS-STAT3rx in Patients With Cancer

3 June 2013

NewLink Genetics’ Algenpantucel-L Shows Encouraging Disease-Free and Overall Survival in Phase 2 Study in Resected Pancreatic Cancer

3 June 2013

Phase I/II Data of VB-111 Demonstrate Anti-Tumor Effects with Increase in Overall Survival with This Anti-Angiogenic Gene Therapy, in Patients with Recurrent Glioblastoma Multiforme

3 June 2013

Advaxis Reports Survival and New Analysis for ADXS-HPV in Patients with Recurrent Cervical Cancer at the 2013 American Society of Clinical Oncology Annual Meeting

1 June 2013

NewLink Genetics Presents Positive Phase 2 Data on Novel Immunotherapy, Tergenpumatucel-L, in Non-Small Cell Lung Cancer at the ASCO 2013 Annual Meeting

1 June 2013

ZIOPHARM Announces Presentation of Updated Results From Ad-RTS-IL-12 Phase I Study in Advanced Melanoma at the 2013 ASCO Annual Meeting

1 June 2013

Amgen Presents Positive Results From Talimogene Laherparepvec Phase 3 Study In Patients With Metastatic Melanoma

30 May 2013

FDA-Approved Clinical Trial to Test Effectiveness of Fat-Derived Regenerative Cells on Heart Failure Patients

30 May 2013

International Stem Cell Corporation Initiates IND-Enabling Study in Parkinson’s Disease Program

28 May 2013

Interim data from clinical trial of ReNeuron’s stem cell therapy for stroke to be presented at leading stroke conference. Longer term data continue to show good safety profile and evidence of sustained reductions in neurological impairment and spasticity

28 May 2013

Neuralstem’s Cells Induce Improvement In Acute Spinal Cord Injury Rats, UCSD Study Shows

28 May 2013

Arrowhead Files to Begin Phase 1 Trial of RNAi Therapeutic ARC-520 Against Chronic Hepatitis B Infection

22 May 2013

Oncolytics Biotech Inc. Meets Primary Endpoint for First Stage of U.S. Phase 2 Metastatic Melanoma Trial

21 May 2013

Jennerex Announces Completion of Enrollment in Phase 2b Clinical Trial of Pexa-Vec for the Treatment of Liver Cancer

20 May 2013

Sangamo BioSciences Presents New Data From In Vivo Protein Replacement Platform For Development Of ZFP Therapeutics For Monogenic Diseases

17 May 2013

Alnylam Presents Key Pre-Clinical Proof-of-Concept Data for ALN-AS1, an RNAi Therapeutic Targeting Aminolevulinate Synthase-1 (ALAS-1) for the Treatment of Porphyria

13 May 2013

Marina Biotech Announces That Licensee Mirna Therapeutics Reported Initiation of a Phase 1 Clinical Trial of Anticancer Drug MRX34

8 May 2013

Cell Medica Announces Treatment of First Pediatric Patient in Early Stage Clinical Trial of Cytovir ADV

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Omalizumab (Xolair) Biosimilars & Biosuperiors Pipeline Review

TCR Engineered T-Cell Therapy 2018: an industry analysis of technologies, pipelines, stakeholders & deals

DLL3-Targeted Immunotherapy Candidates Pipeline Review

Aflibercept (Eylea) Biosimilars Pipeline Review

Report Package: TCR-Based Antibody and T-Cell Immunotherapy

GPC3-Targeted Immunotherapy Pipeline Review

Nectin-4-Targeted Immunotherapy Pipeline Review

IGF-1R- and IGF-1 Targeted Immunotherapy Pipeline Review

TROP-2-Targeted Immunotherapy Pipeline Review

Denosumab (Prolia & Xgeva) Biosimilars Pipeline Review